Dr. Garon on Immunotherapy Combinations in NSCLC

Video

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses immunotherapy combinations in non–small cell lung cancer.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses immunotherapy combinations in non—small cell lung cancer (NSCLC).

Although the combination of immunotherapy and chemotherapy has historically been controversial in the NSCLC treatment landscape, Garon says that results from trials such as IMpower150 have begun to provide clarity. In the IMpower150 trial, patients who received the atezolizumab (Tecentriq) along with bevacizumab (Avastin) and chemotherapy had a median progression-free survival (PFS) of 8.3 months compared with 6.8 months with bevacizumab and chemotherapy. This translated to a 38% reduction in the hazard for progression or death.

Additionally, data from CheckMate-227 of nivolumab (Opdivo) plus ipilimumab (Yervoy) in treatment-naïve patients with NSCLC with high tumor mutation burden (TMB) more than tripled the 1-year PFS rate versus chemotherapy. The 1-year PFS rate was 43% for patients with high TMB (≥10 mutations/megabase) assigned to the immunotherapy combination compared with 13% for those assigned to platinum-doublet chemotherapy.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,